| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Efficacy and safety of sirolimus in the treatment of gastrointestinal angiodysplasias
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Qi Sun, Jin-Cheng Wu, Xiao Chen, Dong-Hao Li, Bai-Rong Li, Nian-Jun Xiao, Xiao-Ying Wang, Xin-Zhuo Tu, Shou-Bin Ning and Tao Sun |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Air Force Medical Center Youth Talent Program Project |
No. 22YXQN034 |
| Capital Health Development Research Special Project |
No. 2020-4-5123 |
| Beijing Haidian District Health and Wellness Development Scientific Research Cultivation Program |
No. HP2021-03-80803 |
|
| Corresponding Author |
Tao Sun, MD, PhD, Department of Gastroenterology, Air Force Medical Center, No. 30 Fucheng Road, Haidian District, Beijing 100142, China. suntao8703@126.com |
| Key Words |
Gastrointestinal angiodysplasias; Sirolimus; Bleeding; Efficacy; Safety |
| Core Tip |
This study indicates that sirolimus, a mammalian target of rapamycin inhibitor, effectively reduces bleeding episodes and improves hemoglobin levels in patients with gastrointestinal angiodysplasias (GIAD). By decreasing transfusions requirements and reducing vascular lesions, sirolimus shows promise as a novel therapeutic strategy. The treatment was generally well-tolerated, with mild and manageable side effects. While these findings are encouraging, future larger, controlled trials are needed to validate sirolimus’s role in managing GIAD. |
| Publish Date |
2025-07-04 09:23 |
| Citation |
<p>Sun Q, Wu JC, Chen X, Li DH, Li BR, Xiao NJ, Wang XY, Tu XZ, Ning SB, Sun T. Efficacy and safety of sirolimus in the treatment of gastrointestinal angiodysplasias. <i>World J Gastroenterol</i> 2025; 31(25): 105677</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v31/i25/105677.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v31.i25.105677 |
